Product overview with focus on rare and special diseases.
AOP Orphan's focus is on rare and special diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Intensive Care. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to rare and special diseases.
is indicated for the rapid control of mild-to-moderate agitation (increased, unproductive physical activity coupled with internal tension) in adult patients with schizophrenia or biopolar disorder.
Adepend is used as part of a comprehensive treatment programme against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.
is used to treat pulmonary arterial hypertension in adults.
Anagrelide AOP is indicated in Essential Thrombocythemia for the reduction of elevated platelet counts and associated clinical symptoms in at high risk patients
BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.
Canemes® is indicated for the treatment of nauseas and vomiting in adults who do not adequately respond to other anti-emetic treatment options.
Empressin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.
Esmolol hydrochloride is indicated for supraventricular tachycardia (except for pre-excitation syndromes) and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated for tachycardia and hypertension occurring in the perioperative phase and non-compensatory sinus tachycardia where, in the physician’s judgement the rapid heart rate requires specific intervention.
Motetis is used as symptomatic therapy in the treatment of Huntington’s disease.
is prescribed for short-term relief of moderate to severe pain e.g. post-surgery, in labour pain and gynecology, in myocardial infarction. Antagonizing an opioid induced respiratory depression, e.g. following fentanyl-combined narcosis. use in a combined narcosis ."
Complete or partial reversal of CNS depressive effects, especially respiratory depression, caused by natural or synthetic opioids and partial agonist/antagonist opioids. It is also used to diagnose a suspected acute opioid overdose or intoxication or to reduce the effect of opioids, which were used for anesthesia in operations.
Ocaliva® is indicated for the treatment of primary biliary cholangitis (also known to as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
Ospolot® is an antiepileptic drug and is used to treat Rolandic epilepsy.
is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures.
Landiolol hydrochloride is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Landiolol hydrochloride is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. Landiolol is not intended for use in chronic settings.
Treatment of idiopathic or hereditary pulmonary arterial hypertension (PAH) for improving exercise capacity and alleviate disease symptoms in patients with New York Heart Association (NYHA) Functional Class III.
Treatment of idiopathic or hereditary pulmonary arterial hypertension (PAH) for improving exercise capacity and alleviate disease symptoms in patients with New York Heart Association (NYHA) Functional Class III.
Tadalafil AOP is used to treat adults with pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity).
Tardiben® tablets are indicated for hyperkinetic motor disorders associated with Huntington’s chorea.
Tetmodis® is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease.
Tetrabenazine is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease.
Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients
Treprostinil Amomed® is used to treat pulmonary arterial hypertension.
Trepulmix is indicated for the treatment of adult patients with WHO Functional Class (FC) III or IV and - inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or - persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.
Wakix® is indicated in adults for the treatment of narcolepsy with or without cataplexy.